Eradication of Staphylococcus aureus nasal colonization by engineered lytic phage proteins

BMBF-DZIF TTU 08.807als assoziierte Partnereinrichtung im Rahmen der Thematic Translational Unit (TTU) HAARBI (Healthcare-associated and Antibiotic-resistant Bacterial Infections) des Deutschen Zentrums für Infektionsforschung (DZIF)as external partner within the Thematic Translational Unit (TTU) HAARBI (Healthcare-associated and Antibiotic-resistant Bacterial Infections) of the German Center for Infection Research (DZIF)
K. Becker, G. Peters
01/2013 – 12/2015
Based on in pilot projects generated engineered lytic phage proteins will be further optimized in terms of in vivo activity and stability and additional novel phage lysins will be developed as an alternative therapeutic approach for eradication of nasal S. aureus/MRSA colonization. Minimal inhibitory concentration (MIC) and minimal bactericidal concentration (MBC) assays as well as other activity-determining parameter will be tested in comparison to mupirocin for analyses of phage lysins´ anti-S. aureus activity and specificity.

Staphylococcal phenotypes: Normal and small colony variant (SCV) phenotype